Drug intelligence / Profile preview

CD19-directed CAR-T cells (Chinese PLA General Hospital)

Development stage: Unknown
Lead developer: Chinese PLA General Hospital
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

CD19-directed CAR-T cells developed by the Chinese PLA General Hospital are an investigational allogeneic (donor-derived) chimeric antigen receptor T-cell therapy. This specific treatment is being evaluated in Phase I clinical trials for patients with relapsed or refractory B-cell malignancies, including B-cell acute lymphoblastic leukemia (B-ALL) and B-cell lymphoma. The therapy involves engineering T cells from a healthy donor to express a CAR targeting the CD19 antigen, which is widely expressed on B-cell lineage cells. In the clinical protocol described, these CAR-T cells are administered prior to a donor-derived hematopoietic stem cell transplant (HSCT) to eradicate residual disease and potentially enhance the graft-versus-leukemia (GVL) effect while minimizing the risk of CD19-negative relapse.

Other names: Donor-derived CD19-directed CAR-T cellsAllo-CD19-CAR-T cellsAllo-CD-19-CAR-T cellsAllo-CD 19-CAR-T cells

Targets

CD19 (B lymphocyte antigen CD19)

Beyond the preview

Go deeper on CD19-directed CAR-T cells (Chinese PLA General Hospital).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CD19-directed CAR-T cells (Chinese PLA General Hospital).

Explore the full profile